EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Multivitamins After Myocardial Infarction in Patients With Diabetes

Francisco Ujueta, Gervasio A Lamas, Kevin J Anstrom, Ana Navas-Acien, Robin Boineau, Yves Rosenberg, Mario Stylianou, Teresa L Z Jones, Bonnie R Joubert, Qilu Yu, Jun Wen, Hayley Nemeth und 12 weitere

JAMA Internal Medicine · 2025

DOI: 10.1001/jamainternmed.2024.8408 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, 2025. Verfasst von Francisco Ujueta und 23 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital Division of Cardiovascular Medicine, Boston, Massachusetts. Hauptthemen laut MEDLINE: Myocardial Infarction, Vitamins, Diabetes Mellitus, Chelation Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In 2013, the Trial to Assess Chelation Therapy (TACT) reported that in 1708 patients with stable coronary disease and prior myocardial infarction (MI), oral multivitamins and multiminerals (OMVMs), in a factorial design with edetate disodium (EDTA) chelation therapy, did not reduce cardiovascular events relative to placebo OMVMs, but active EDTA combined with active OMVMs was superior to placebo OMVM/placebo EDTA.

Objective

To compare OMVM vs placebo in terms of efficacy for reducing major adverse cardiovascular events in patients with diabetes and prior MI. Design, Setting, and Participants The TACT2 randomized, multicenter double-masked 2 × 2 factorial clinical trial took place across 88 sites in the US and Canada. Participants were 50 years or older, had diabetes, and had an MI 6 weeks ago or more. TACT2 participants were enrolled between September 2016 and December 2020. Data were collected between October 2016 and June 2023.

Interventions

Six caplets daily of a 28 component OMVM or matching OMVM placebo, and 40 weekly infusions of an EDTA-based chelation solution or matching placebo, in a 1:1:1:1 allocation ratio. Main Outcomes and Measures The primary end point was the composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina.

Results

A total of 1000 participants were randomized (500 in the active OMVM group and 500 in the placebo group). The median (IQR) age was 67 (60-72) years, and 730 (73%) were male. Median (IQR) follow-up was 48 (34-58) months. The primary end point occurred in 175 participants (35%) in the active OMVM group and 175 (35%) in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.80-1.22]; P = .92). The 5-year event rate for the primary end point in the EDTA chelation + active OMVM group was 34.0%; in the EDTA chelation + placebo OMVM group, 35.7%; in the placebo infusion + active OMVM group, 36.0%; and in the placebo infusion + placebo OMVM group, 34.3%. The comparison of the active infusion + active OMVM with the placebo infusion + placebo OMVM was not significant (HR, 0.91 [95% CI, 0.67-1.23]; P = .54). Although nonsignificant, there was a numerically higher event rate of MI, stroke, mortality from cardiovascular causes in the active OMVM compared to placebo OMVM group. Conclusions and Relevance The results of this randomized clinical trial demonstrated that, for participants with chronic coronary disease, diabetes, and a previous MI, high-dose OMVM alone or in conjunction with EDTA-based chelation did not reduce cardiovascular events. Trial Registration ClinicalTrials.gov Identifier: NCT02733185

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionVitaminsDiabetes MellitusChelation TherapyHumansMaleFemaleDouble-Blind MethodAgedMiddle AgedEdetic Acid

Substanzen

VitaminsEdetic Acid

Autor:innen und Institutionen

  • Brigham and Women's Hospital Division of Cardiovascular Medicine, Boston, Massachusetts.
  • Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, Florida.
  • Gillings School of Global Public Health, University of North Carolina, Chapel Hill.
  • Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York.
  • National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, Maryland.
  • National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Zitieren

APA

Ujueta, F., Lamas, G. A., Anstrom, K. J., Navas-Acien, A., Boineau, R., Rosenberg, Y., Stylianou, M., Jones, T. L. Z., Joubert, B. R., Yu, Q., Wen, J., Nemeth, H., Huang, Z., Fonseca, V., Nathan, D. M., Uwaifo, G., Arenas, I. A., Luo, L., Baker, J., …, & TACT2 Investigators (2025). Multivitamins After Myocardial Infarction in Patients With Diabetes. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.8408

Vancouver

Ujueta F, Lamas GA, Anstrom KJ, Navas-Acien A, Boineau R, Rosenberg Y, et al. Multivitamins After Myocardial Infarction in Patients With Diabetes. JAMA Internal Medicine. 2025. doi:10.1001/jamainternmed.2024.8408

BibTeX
@article{Ujueta2025,
  author = {Ujueta, Francisco and Lamas, Gervasio A and Anstrom, Kevin J and Navas-Acien, Ana and Boineau, Robin and Rosenberg, Yves and Stylianou, Mario and Jones, Teresa L Z and Joubert, Bonnie R and Yu, Qilu and Wen, Jun and Nemeth, Hayley and Huang, Zhen and Fonseca, Vivian and Nathan, David M and Uwaifo, Gabriel and Arenas, Ivan A and Luo, Lan and Baker, Jeffrey and Visentin, Diana and Paixao, Andre and Schmedtje, John F and Mark, Daniel B and TACT2 Investigators, TACT2 Investigators},
  title = {Multivitamins After Myocardial Infarction in Patients With Diabetes},
  journal = {JAMA Internal Medicine},
  year = {2025},
  doi = {10.1001/jamainternmed.2024.8408}
}
Kostenlos starten →